Table 4

Change in Outcome Measures after 8 weeks (For subjects with at least 80% compliance) (n = 27-37)

Variable

Blend 1

(mean ± SD)

Blend 2

(mean ± SD)

Placebo

(mean ± SD)


Endothelial Function

Flow-mediated dilatation, %

0.60 ± 4.30

1.00 ± 3.401

0.60 ± 4.20

Stimulus-adjusted response measure

-0.04 ± 0.33

-0.04 ± 0.28

-0.05 ± 0.28

Serum Measures

Insulin, pmol/L

65.28 ± 362.53

-29.17 ± 232.66

20.14 ± 225.71

Fasting plasma glucose, mmol/L

0.16 ± 1.75

0.11 ± 1.69

0.07 ± 1.61

Anthropometric Measures

Body Weight, kg

0.90 ± 2.90

0.20 ± 2.50

0.40 ± 2.00

Body Mass Index, kg/m2

0.30 ± 0.90

0.00 ± 0.80

0.10 ± 0.70

Lipid Panel

Total Cholesterol, mmol/L

0.10 ± 0.62

0.04 ± 0.49

0.01 ± 0.62

High Density Lipoprotein (HDL), mmol/L

0.04 ± 0.21

0.06 ± 0.15

0.10 ± 0.17

Total Cholesterol/HDL

-0.10 ± 0.70

0.00 ± 0.801

-0.40 ± 0.80

Triglycerides, mmol/L

0.03 ± 0.71

0.24 ± 0.60

-0.19 ± 0.87

Low Density Lipoprotein (LDL), mmol/L

-0.04 ± 0.71

0.11 ± 0.55

-0.01 ± 0.74


1 p = 0.02 as compared to placebo;

Ali et al. Nutrition Journal 2011 10:72   doi:10.1186/1475-2891-10-72

Open Data